Stratolaunch successfully completed its hypersonic test flight earlier this year. Image courtesy of Draper

With a recent air-launched test vehicle flight that came close to hypersonic speed, research company Draper has accelerated the potential for its flight technology.

Draper, a Cambridge, Massachusetts-based nonprofit, provided the crucial guidance, navigation, and control flight software for the flight. That guidance system was built on the same Draper technology that NASA has used in its Apollo mission, the international space station and space shuttle programs.

“In a broad sense, Draper has been working hypersonic since Apollo,” Rick Loffi, space systems program manager and lead executive for Draper’s Houston campus, tells InnovationMap.

The navigation software controlled the first powered test flight of an air-launched vehicle that approached the hypersonic threshold of Mach 5, or 3,800 miles per hour, or five times the speed of sound.

Stratolaunch successfully completed the flight of its TA-1 Talon test vehicle in the Mojave Desert in March. The California-based company designs and launches aerospace vehicles and technologies, providing access to a reusable hypersonic testing platform, according to its website. The historic test flight landed in the Pacific Ocean, and achieved successful ignition, acceleration and sustained altitude climb.

“The Draper software is really what’s stabilizing the vehicle during flight…and controlling it as it gets up into altitude and speed,” Brandon Jalbert, space systems program manager for Draper and team lead for Stratolaunch, says “so it’s not doing loop-de-loops, or getting unstable…blowing up in the atmosphere.”

Draper uses model-based design and algorithms in its software, and for the boost phase of the Talon test, Draper developed a novel algorithm, which built upon its previous work for NASA, Jalbert says.

Aerospace manufacturing companies like Boom and Hermeus stand poised to pick up where the Concorde left off, and are racing to implement and execute on accessible hypersonic and supersonic commercial technology.

The Concorde aircraft made supersonic, four-hour transoceanic flights a reality, but only for the very wealthy, and shut down in 2003.

Draper is not involved in any of those ventures to bring accessible supersonic flight back to the skies. Its primary focus with hypersonic will remain with deterrence and testing platforms, Jalbert says.

But the company’s technology “has applications everywhere from military to commercial activity,“ he says.

“Our focus is to solve complex challenges of national importance,” he says, “whether that’s…helping our commercial partners, or working on civil or military applications. That’s where we see ourselves being of value to the industry.”

With the harsh conditions involved in hypersonic flight, advancing the technology has its challenges.

“You’ve got to have proper hardware and electronics and sensors that can operate within those conditions,” Jalbert says.

Draper originated in 1932 when engineer Charles Stark Draper founded what eventually became the Instrumentation Lab at MIT.

His work on inertial navigation theory paved the way for the use of the autopilot in today’s commercial jets. The lab was divested by MIT in the 1970s, and became a nonprofit. Draper has long been a government contractor and has worked on many military projects, dating to WWII.

Draper in 2023 secured the $2.2 billion renewal of a long-standing contract with the U.S. Navy to provide the guidance system for the submarine-launched Trident II D-5 missile.

The U.S. government has shown a growing interest in the development of hypersonic weapons systems, as Russia and China have developed advanced capabilities.

The Pentagon’s budget request for hypersonic research for fiscal year 2025 was $6.9 billion, up from $4.7 billion for 2023, according to a recent U.S. Naval Institute report.

“There’s a big shift, in deterrence, as well as offensive, on hypersonic,” Jalbert says.

However, the Defense Department has not yet acquired hypersonic weapons, according to the report, but is developing prototypes and testing.

Draper has a long, celebrated history with NASA, and its Houston office is housed at Johnson Space Center. Draper's presence in Houston dates back to the 1960s, Loffi says.

From the Apollo missions to the space station and now the Artemis program, which aims to land the first person of color and the first woman on the moon by 2026 on its Orion spacecraft, Draper has partnered with NASA every step of the way, providing its navigation system for space flight.

“Right now, our biggest customer within NASA is the Orion program,” Loffi says, with approximately 15 of the 20-person Houston office working on the project, in collaboration with the company’s Cambridge colleagues.

Draper's Houston office is working on NASA's Orion program. Photo via NASA

The company is also working with NASA on lunar landing technology and sub-orbital experiments, as well as the propulsion element and Gateway space station for Artemis.

Amazon founder Jeff Bezos’s aerospace manufacturing company Blue Origin is also partnering with Draper to develop the Artemis human landing system.

Neither Loffi nor Jalbert aspired to go into outer space themselves, but rather to provide solutions to make that possible. Human spaceflight has been a lifelong passion for Loffi.

While he had lots of job opportunities after graduating from Purdue University with a degree in electrical engineering, Loffi chose NASA.

“I wasn’t that person who grew up dreaming of becoming an astronaut,” Loffi says. “I was old enough to see the Apollo 11 moon landing, and it did inspire me.”

His work at NASA began after the space shuttle Challenger explosion, in 1986. He was part of the agency’s effort to return to space flight, and worked on space station development, before joining Draper in 2011.

Jalbert, a graduate of Northeastern University, says his early work at Draper “lit the fires for my interest in space.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”